MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-21-2023
Timber Pharmaceuticals Operating Income 2011-2026 | TMBR
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Timber Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.2 M | -10.7 M | -20.2 M | -3.04 M | -16.9 M | -18.4 M | -15.2 M | - | -7.77 M | -1.51 M | -28 K | -59.1 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -28 K | -20.2 M | -10.3 M |
Quarterly Operating Income Timber Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4 M | -4 M | - | -3.13 M | -9.4 M | -3.14 M | - | -3 M | -2.97 M | -1.87 M | - | -1.59 M | -14.3 M | -1.62 M | - | -577 K | -190 K | -3.64 M | - | -4.45 M | -4.47 M | -4.36 M | - | -3.74 M | -4.27 M | -5.03 M | - | -4.16 M | -5.04 M | -4.46 M | - | -3.85 M | -3.57 M | -3.19 M | - | -2.19 M | -1.79 M | -1.28 M | - | -429 K | -247 K | -2.31 K | -2.78 K | -8.15 K | -1.55 K | -95.4 K | -1.3 K | -5.94 K | -1.05 K | -1.3 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.05 K | -14.3 M | -2.75 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.56 | 2.01 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 703.3 | 0.41 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
ADC Therapeutics SA
ADCT
|
-262 M | $ 4.22 | 2.18 % | $ 105 M |  Schweiz |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 6.63 | -0.75 % | $ 182 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.36 | 1.13 % | $ 210 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 90.54 | -0.71 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.05 | 1.64 % | $ 1.31 B | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-181 M | $ 6.05 | -0.82 % | $ 493 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.64 | 3.94 % | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
BioCardia
BCDA
|
-11.6 M | $ 1.27 | 0.79 % | $ 26.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.51 | 4.86 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 3.58 | -0.56 % | $ 7.79 B | Israel |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
-42.1 M | $ 1.11 | - | $ 33.4 M | USA |